Log in

NASDAQ:TBPHTheravance Biopharma Stock Price, Forecast & News

$26.69
-0.69 (-2.52 %)
(As of 05/26/2020 04:00 PM ET)
Add
Compare
Today's Range
$26.13
Now: $26.69
$28.00
50-Day Range
$22.56
MA: $27.18
$30.69
52-Week Range
$15.18
Now: $26.69
$31.54
Volume268,318 shs
Average Volume230,345 shs
Market Capitalization$1.68 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.54
Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant. YUPELRI, a long-acting muscarinic antagonist, for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD); and Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders. The company's product candidates also comprise Selective 5-HT4 Agonist for treating gastrointestinal motility disorders; Gut-selective Pan-Janus Kinase Inhibitor Program for treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis; TD-9855, an investigational norepinephrine and serotonin reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TD-0714 and Neprilysin Inhibitor Program, which have completed Phase I clinical studies for heart failure and chronic kidney disease, including diabetic nephropathy. In addition, it focuses on various drug development programs, including the combination of fluticasone furoate, umeclidinium bromide, and vilanterol for the treatment of COPD and asthma; the inhaled bifunctional muscarinic antagonist-beta2 agonist program, as monotherapy; and in combination with other therapeutically active components, such as an inhaled corticosteroid. The company was incorporated in 2013 and is based in George Town, the Cayman Islands.
Read More
Theravance Biopharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.49 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TBPH
Previous SymbolNASDAQ:TBPHV
CUSIPN/A
Phone650-808-6000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$73.41 million
Book Value($2.50) per share

Profitability

Net Income$-236,460,000.00
Net Margins-280.80%

Miscellaneous

Employees363
Market Cap$1.68 billion
Next Earnings Date7/29/2020 (Estimated)
OptionableOptionable

Receive TBPH News and Ratings via Email

Sign-up to receive the latest news and ratings for TBPH and its competitors with MarketBeat's FREE daily newsletter.

Theravance Biopharma (NASDAQ:TBPH) Frequently Asked Questions

How has Theravance Biopharma's stock been impacted by COVID-19 (Coronavirus)?

Theravance Biopharma's stock was trading at $24.80 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, TBPH stock has increased by 7.6% and is now trading at $26.69. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Theravance Biopharma?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Theravance Biopharma in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Theravance Biopharma.

When is Theravance Biopharma's next earnings date?

Theravance Biopharma is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for Theravance Biopharma.

How were Theravance Biopharma's earnings last quarter?

Theravance Biopharma Inc (NASDAQ:TBPH) announced its quarterly earnings results on Wednesday, May, 6th. The biopharmaceutical company reported ($1.40) earnings per share for the quarter, missing analysts' consensus estimates of ($1.07) by $0.33. The biopharmaceutical company earned $19.86 million during the quarter, compared to analysts' expectations of $18.02 million. View Theravance Biopharma's earnings history.

What price target have analysts set for TBPH?

6 brokerages have issued twelve-month price targets for Theravance Biopharma's shares. Their forecasts range from $18.00 to $55.00. On average, they anticipate Theravance Biopharma's stock price to reach $37.00 in the next twelve months. This suggests a possible upside of 38.6% from the stock's current price. View analysts' price targets for Theravance Biopharma.

Has Theravance Biopharma been receiving favorable news coverage?

Media headlines about TBPH stock have been trending positive on Wednesday, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Theravance Biopharma earned a coverage optimism score of 2.7 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutTheravance Biopharma.

Are investors shorting Theravance Biopharma?

Theravance Biopharma saw a drop in short interest in April. As of April 30th, there was short interest totaling 2,850,000 shares, a drop of 6.3% from the April 15th total of 3,040,000 shares. Based on an average trading volume of 470,600 shares, the short-interest ratio is currently 6.1 days. Currently, 6.5% of the company's shares are short sold. View Theravance Biopharma's Current Options Chain.

Who are some of Theravance Biopharma's key competitors?

What other stocks do shareholders of Theravance Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Theravance Biopharma investors own include Gilead Sciences (GILD), Bausch Health Companies (BHC), Teva Pharmaceutical Industries (TEVA), Exelixis (EXEL), Immunomedics (IMMU), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), SCYNEXIS (SCYX), GW Pharmaceuticals PLC- (GWPH) and Coca-Cola (KO).

Who are Theravance Biopharma's key executives?

Theravance Biopharma's management team includes the following people:
  • Mr. Rick E. Winningham, Chairman & CEO (Age 59)
  • Mr. Bradford J. Shafer, Exec. VP, Gen. Counsel & Sec. (Age 59)
  • Dr. Shehnaaz Suliman M.D., M.Phil., M.B.A., Sr. VP of Corp. Devel. & Strategy (Age 46)
  • Dr. Brett K. Haumann, Sr. VP of Clinical Devel. & Chief Medical Officer (Age 49)
  • Mr. Vijay Sabesan, Sr. VP of Technical Operations

What is Theravance Biopharma's stock symbol?

Theravance Biopharma trades on the NASDAQ under the ticker symbol "TBPH."

Who are Theravance Biopharma's major shareholders?

Theravance Biopharma's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (13.94%), Link Fund Solutions Ltd (7.68%), Wellington Management Group LLP (6.61%), State Street Corp (1.68%), Chescapmanager LLC (1.59%) and Perceptive Advisors LLC (1.59%). Company insiders that own Theravance Biopharma stock include Bradford J Shafer, Donal O'connor, Philip D Worboys, Renee D Gala, Sharathchandra S Hegde and Vijay Sabesan. View institutional ownership trends for Theravance Biopharma.

Which major investors are selling Theravance Biopharma stock?

TBPH stock was sold by a variety of institutional investors in the last quarter, including Link Fund Solutions Ltd, Chicago Equity Partners LLC, King Wealth, Ensign Peak Advisors Inc, and Virtus ETF Advisers LLC. View insider buying and selling activity for Theravance Biopharma.

Which major investors are buying Theravance Biopharma stock?

TBPH stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Perceptive Advisors LLC, Wellington Management Group LLP, Federated Hermes Inc., Orbimed Advisors LLC, Tekla Capital Management LLC, Geode Capital Management LLC, and State Street Corp. View insider buying and selling activity for Theravance Biopharma.

How do I buy shares of Theravance Biopharma?

Shares of TBPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Theravance Biopharma's stock price today?

One share of TBPH stock can currently be purchased for approximately $26.69.

How big of a company is Theravance Biopharma?

Theravance Biopharma has a market capitalization of $1.68 billion and generates $73.41 million in revenue each year. The biopharmaceutical company earns $-236,460,000.00 in net income (profit) each year or ($4.25) on an earnings per share basis. Theravance Biopharma employs 363 workers across the globe.

What is Theravance Biopharma's official website?

The official website for Theravance Biopharma is www.theravance.com.

How can I contact Theravance Biopharma?

Theravance Biopharma's mailing address is UGLAND HOUSE SOUTH CHURCH STREET, GEORGE TOWN E9, KY1-1104. The biopharmaceutical company can be reached via phone at 650-808-6000 or via email at [email protected]

This page was last updated on 5/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.